Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Core Viewpoint - Aprea Therapeutics has announced an oversubscribed private placement financing expected to generate approximately $30 million in gross proceeds for the company, aimed at supporting its research and development efforts in precision medicine oncology [1][4]. Financing Details - The private placement was led by Soleus Capital, with participation from Vestal Point Capital, Squadron Capital Management, existing investors, and certain insiders of the company [2]. - The financing will involve the sale of pre-funded warrants to purchase approximately 37.2 million shares of common stock at a price of $0.808 per warrant, and additional warrants with an exercise price of $0.683 per share [3]. Use of Proceeds - The company plans to utilize the net proceeds from the private placement for general corporate purposes and research and development expenses [4]. - Aprea aims to extend its cash runway into the first quarter of 2028, based on current business plans and assumptions [5]. Clinical Development - Aprea is focused on enrolling at least 50 patients with uterine serous carcinoma and patients with Cyclin E-overexpressing, platinum-resistant ovarian cancer in its ongoing ACESOT-1051 Phase 1 trial [5]. - The company anticipates completing dose escalation of the ACESOT-1051 trial in the second quarter of 2027 [5]. Company Overview - Aprea Therapeutics is a clinical-stage precision medicine oncology company dedicated to developing targeted therapies for biomarker-defined cancers, with a focus on exploiting vulnerabilities associated with cancer cell mutations [9]. - The company's lead programs include APR-1051, an oral small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications [9].